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Here we report the rescue of a recombinant porcine reproductive and respiratory syndrome virus (PRRSV) carrying
an enhanced green fluorescent protein (EGFP) reporter gene as a separate transcription unit. A copy of the
transcription regulatory sequence for ORF6 (TRS6) was inserted between the N protein and 3′-UTR to drive the
transcription of the EGFP gene and yield a general purpose expression vector. Successful recovery of PRRSV was
obtained using an RNA polymerase II promoter to drive transcription of the full-length virus genome, which was
assembled in a bacterial artificial chromosome (BAC). The recombinant virus showed growth replication characteristics
similar to those of the wild-type virus in the infected cells. In addition, the recombinant virus stably expressed EGFP for
at least 10 passages. EGFP expression was detected at approximately 10 h post infection by live-cell imaging to follow
the virus spread in real time and the infection of neighbouring cells occurred predominantly through cell-to-cell-contact.
Finally, the recombinant virus generated was found to be an excellent tool for neutralising antibodies and antiviral
compound screening. The newly established reverse genetics system for PRRSV could be a useful tool not only to
monitor virus spread and screen for neutralising antibodies and antiviral compounds, but also for fundamental research
on the biology of the virus.Introduction
Porcine reproductive and respiratory syndrome (PRRS),
characterized by respiratory diseases in nursery pigs and
reproductive failure in sows [1,2], has become one of the
most economically important infectious diseases in the
global swine industry [3]. PRRS virus (PRRSV), the causa-
tive agent of PRRS, is a member of a group of enveloped
RNA viruses from the genus Arterivius of the family
Arteriviridae within the order Nidovirales. PRRSV genome* Correspondence: zhouem@nwsuaf.edu.cn
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reproduction in any medium, provided the oris a linear, non-segmented, single stranded, positive-sense
RNA with 15 kb in size [4], capped at the 5′ end and poly-
adenylated at the 3′ terminus. The PRRSV genome con-
sists of at least six genes, encoding the structural proteins
GP2 or GP2a, GP3, GP4, GP5, M, and N, which are in the
order of 5′-ORF1-GP2-GP3-GP4-GP5-M-N-3′ on the gen-
ome [5,6]. Two distinct genotypes of PRRSV, the European
genotype (type 1) and North American genotype (type 2)
[2,7-10], share only 60% nucleotide identity and are repre-
sented by the North American prototype VR-2332 and the
European prototype Lelystad virus (LV) [11]. In 2006, the
highly pathogenic PRRS (HP-PRRS), characterized by high
fever, high morbidity and mortality in pigs of all ages, oc-
curred in China and resulted in the culling of an estimated
20 million pigs in 2006–2007 [12]. The causative agent of
HP-PRRS is HP-PRRSV and was more virulent than the
classical PRRSV [13]. Genomic analysis showed thattd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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discontinuous deletion of 30 amino acids (aa) in non-
structural protein 2 (Nsp2). However, a number of
newly isolated PRRSV variants with different deletions
or recombinants was reported in China and the HP-
PRRSV variant continues prevailing and accelerating
evolution in China [14-16].
Over the past decade, reverse genetics systems devel-
oped for the study of many of the positive-stranded
RNA viruses can generate recombinant mutant viruses
to study different aspects of virus biology. In particular,
recombinant viruses expressing reporter proteins have
been instrumental in tracking viral infection and spread
in vivo, as well as in the development of novel antiviral
drugs [17-22]. In PRRSV, rescue systems to recover in-
fectious viruses from full length complementary DNA
(cDNA) clones have been established for type 1 and type
2 PRRSV to understand the viral life cycle, determine
the function of viral protein, and study mutant virus
pathogenesis [23-34]. Green fluorescent protein (GFP)
and its variant enhanced GFP (EGFP) inserted into a
number of viral genomes have become the widely used
reporter genes to study viral entry mechanisms, observe
the transport of viral nucleic acids in and out of the nu-
cleus region, track the assembly and transport of newly
synthesized viral components, and visualize the cell-to-
cell spread of newly synthesized viral particles [35-40].
Several studies have indicated that the presence of
overlapping genes in arteritis virus genomes hampers
mutational analysis of the N- and C-termini of the struc-
tural proteins and also makes it difficult to insert heter-
ologous genes into the viral genome [22,41,42]. The first
recombinant HA-tagged PRRSV lost foreign HA epitope
fused with the ORF7 from the second passage [43]. The
rescued PRRSV with the green fluorescent gene fused
with the Nsp2 protein, lost the green fluorescent after 7
serial passages due to the deletion of N-terminal amino
acids (1 to 159aa) of GFP [44] or the accumulation of
point mutations [45]. In addition, apart from the fusion
of the green fluorescent gene with Nsp2, a recombinant
PRRSV expressing GFP gene proved the stability of the
foreign GFP gene even after 37 serial passages. This was
done by using the transcription regulatory sequence of
gene 2 (TRS2) to drive transcription of the GFP gene
and inserting an extra synthetic TRS6 to drive transcrip-
tion of the ORF 2a and 2b [22].
In this study, we developed an HP-PRRSV infectious
clone using a bacterial artificial chromosome (BAC).
This BAC expressed the EGFP gene inserted between
the N gene and the 3′UTR region of the viral genome
with a copy of TRS6 to drive transcription of the EGFP
to create a marker recombinant PPRSV with limited
modification of the genome. This recombinant virus stably
expresses EGFP as a separate transcription unit and wasfound to be a useful tool to monitor virus spread, screen
for neutralising antibodies and antiviral compounds.
Materials and methods
Cell lines, viruses and drugs
HP-PRRSV/SD16 used in this study was isolated from
an intensive pig farm with an atypical PRRS outbreak in
Shandong province of China in 2012 [16]. The complete
cDNA of the HP-PRRSV/SD16 genome was fully se-
quenced and confirmed [GenBank: JX087437]. Marc-145
cells were cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal bovine
serum at 37 °C in a 5% CO2 incubator. The cyclophilin
inhibitors CsA (Bioaustralis) were dissolved in dimethyl
sulfoxide (DMSO). CsA stock at 50 mg/mL was stored
at −20 °C.
Plasmid construction
Prior to introducing the full-length viral cDNA into the
pBeloBAC11, pBAC-SD16-5′-3′ was assembled similarly
as previously described by Almazan et al. and St-Jean
et al. [46,47], using the pBeloBAC11 plasmid as the
backbone. This plasmid includes the first 758 nucleo-
tides (nts) of the genome under the control of the CMV
promoter, and the last 2014 nts of the viral RNA,
followed by a 32-bp synthetic poly (A) tail, the hepatitis
delta virus ribozyme (HDV), and the bovine growth hor-
mone termination and polyadenylation sequences (BGH)
to lead an accurate 3′ end (Figure 1a). In addition, a
multicloning site containing the restriction sites Kas I,
Pml I, Bmt I, Nsi I, Asc I, and Bsu36 I was introduced
between the viral sequences and used to construct the
full-length viral cDNA.
HP-PRRSV/SD16 was propagated in Marc-145 cells
and total RNA was isolated from the infected cells using
TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). The
entire viral genome of HP-PRRSV/SD16 except for the
5′ and 3′ ends was amplified by RT-PCR using Phusion®
High-Fidelity PCR Master Mix (NEB, Ipswich, MA,
USA) in five distinct overlapping regions (named F1 to
F5) (Figure 1a). Each amplicon was inserted into the
pEASY™-blunt simple cloning vector and after sequen-
cing, introduced into the pBAC-SD16-5′-3′ vector to
generate the pBAC-SD16FL (Figure 1a). The unique re-
striction sites inserted into pBAC-SD16FL between nt 15
170 and 15 171 of the HP-PRRSV/SD16 genome cDNA
sequence were used for the cloning of EGFP under the
control of the TRS6. To this end, fragment Fa (ending at
the N gene with AsiS I and Mlu I sites introduced at the
3′ end) and Fm (starting from the 3′-UTR with AsiS I
and Mlu I sites introduced at the 5′ end) were amplified
from pBAC-SD16FL and ligated together to generate
fragment Fam, which was used to replace the fragment
used in the original construction of pBAC-SD16FL to
Figure 1 Construction of plasmids for PRRSV rescue. A. The cDNA fragments F1, F2, F3, F4, and F5 were reversely transcribed and amplified
from HP-PRRSV/SD16 genomic RNA. The CMV promoter was introduced to the 5′ end of HP-PRRSV/SD16 and the hepatitis delta virus ribozyme
(HDV) and the bovine growth hormone termination and polyadenylation sequences (BGH) were included at the 3′ end of HP-PRRSV/SD16. All
fragments were subcloned stepwise into the pBAC-SD16-5′-3′ vector to produce plasmid pBAC-SD16FL. B. DNA fragments Fa (from the genome
position of 11,883 nt to the stop codon of M with AsiS I and Mlu I sites introduced at the 3′ end) and Fm (from start sequence of 3-UTR to the
pBAC-SD16-5′-3′ vector with AsiS I and Mlu I sites introduced at the 5′ end) were PCR-amplified from pBAC-SD16FL and ligated together to form
fragment Fam. The corresponding fragment of pBAC-SD16FL was replaced with Fam to construct plasmid pBAC-SD16FL-AM, which contains AsiS I
and Mlu I sites between nt 15 170 and 15 171 of the HP-PRRSV/SD16 genome cDNA sequence. C. The EGFP with a copy of the transcription
regulatory sequence for ORF6 (TRS6) at the 5′ end of the EGFP sequence was inserted into plasmid pBAC-SD16FL-AM to produce
plasmid pBAC-SD16FL-TRS6-EGFP.
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quence analysis revealed that two unique restriction sites
(AsiS I and Mlu I) were correctly inserted into pBAC-
SD16FL between nt 15 170 and 15 171 of the HP-PRRSV/
SD16 genome.
The EGFP gene was amplified from the pEGFP-N1 Vec-
tor (Clontech, Mountain View, CA, USA) using Phusion®High-Fidelity PCR Master Mix (NEB, Ipswich, MA, USA)
with primers 5′-GCGATCGCTGATGGTTCCGCGGCA
ACCCCTTTAACCAGAGTTTCAGCGGAACAATGGT
GAGCAAGGGCGAGG -3′ (the AsiS I site is underlined),
containing a copy of the TRS6 sequence (in bold), and 5′-
CGACGCGTCGTTACTTGTACAGCTCGTCCA -3′ (the
Mlu I site is underlined). The amplified product was inserted
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plasmids pEASY-TRS6-EGFP, and after sequencing,
cloned into AsiS I / Mlu I-cut pBAC-SD16FL-AM to gen-
erate plasmid pBAC-SD16FL-TRS6-EGFP (Figure 1c). All
primer sequences used in this study are available from the
corresponding author upon request.Transfection and rescue of recombinant viruses
To rescue the recombinant HP-PRRSV/SD16 and HP-
PRRSV/SD16/TRS6-EGFP, 80% confluent Marc-145 cells
cultured in 6-well plates were transfected with the plas-
mids pBAC-SD16FL and pBAC-SD16FL-TRS6-EGFP using
Attractene Transfection Reagent (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions. After
4–5 days of incubation at 37 °C, the cells and supernatants
were collected and freeze-thawed for three times and the
supernatants were then used to infect Marc-145 cells to
propagate the rescued virus. The complete genomic se-
quences of the rescued viruses were confirmed by sequen-
cing. The rescued viruses of HP-PRRSV/SD16 and HP-
PRRSV/SD16/TRS6-EGFP were named rHP-PRRSV/
SD16 and rHP-PRRSV/SD16/TRS6-EGFP, respectively.Propagation of recombinant viruses
Because rHP-PRRSV/SD16/TRS6-EGFP is much easier
for evaluating the reverse genetic system than that for
rHP-PRRSV/SD16, rHP-PRRSV/SD16/TRS6-EGFP was
used in the following experiments. To determine
whether the rescue procedure or exogenous gene inser-
tion affected the replication of the recombinant viruses,
the growth curves of rHP-PRRSV/SD16/TRS6-EGFP
and parental virus were determined by serially passaging
in Marc-145 with a multiplicity of infection (MOI) of
0.01. After 1 h of virus adsorption, the cells were washed
three times with PBS and incubated in DMEM with 3%
FBS at 37 °C in 5% CO2 incubator. The supernatants
were collected at various time points and viral titres
were determined using the Reed-Muench method.Immunofluorescence assays
Marc-145 cells grown on glass cover slips in a 24-well
plate were infected with HP-PRRSV/SD16 or rHP-PRRSV/
SD16/TRS6-EGFP at a MOI of 0.01 for 2 days. Cells were
then fixed with 3% paraformaldehyde. A monoclonal anti-
body (6D10) to PRRSV N protein was used as the primary
antibody and AlexaFluor 568-labelled anti-mouse IgG
(Invitrogen, Carlsbad, CA, USA) was used as the sec-
ondary antibody. In addition, the cells were stained with
4-6-diamidino-2-phenylindole (DAPI) for 5 min at
room temperature. Images were taken by sequential
scanning at each wavelength on a Leica confocal micro-
scope. Mock-infected cells were used as controls.Western blot
Marc-145 cells were infected with HP-PRRSV/SD16 or
rHP-PRRSV/SD16/TRS6-EGFP at a MOI of 0.01 and
cultured until 60% of cells showed the cytopathic effect
(CPE). The infected cells were lyzed and the cellular pro-
teins were separated by SDS-PAGE and blotted on a
polyvinylidene difluoride (PVDF) membrane. The mem-
brane was incubated with mouse anti-GFP monoclonal
antibody, anti-β-Tubulin antibody (Abcam, Cambridge,
MA, USA) and 6D10, as the primary antibodies, and
then with peroxidase-conjugated goat anti-mouse IgG
(Jackson, West Grove, PA, USA) as the secondary anti-
body. Immunostained proteins were visualized using
ECL Western Blotting Substrate (Pierce, Rockford IL,
CA, USA). Cellular proteins from mock-infected Marc-
145 cells were used as controls.
Quantification of EGFP fluorescence
To determine whether repeated passages of rHP-PRRSV/
SD16/TRS6-EGFP in Marc-145 cells affected replication
and expression, the recombinant virus was propagated in
Marc-145 cells for 10 passages and assayed for total (cell-
associated and released into culture media) virus titres
and for EGFP expression using GFP Quantification Kit
(BioVision, Mountain View, CA, USA), according to the
manufacturer’s instructions. Briefly, Marc-145 cells grown
in 6-well plates were infected with rHP-PRRSV/SD16/
TRS6-EGFP at a MOI of 0.01. A total of 106 cultured cells
were freeze-thawed for three times when the cells showed
100% CPE and homogenized with 0.25 mL of assay buffer,
incubated on ice for 10 min and centrifuged for 5 min at
15 000 × g. The supernatants and the medium collected
from the infected cells were stored at −20 °C. A total of
100 μL samples in assay buffer was transferred to wells of
a 96-well white plate (NUNC, Lowell, MA, USA). The
EGFP fluorescence of each well was read on a Microplate
Fluorescence Reader (BioTek, Winooski, VT, USA) at Ex/
Em= 488/507 nm. The quantity of EGFP was determined
by comparing its fluorescence with that of the GFP stand-
ard. Mock-infected cells were used as controls.
In vivo imaging of PRRSV-EGFP expression
Marc-145 cells were infected with rHP-PRRSV/SD16/
TRS6-EGFP at a MOI of 0.01 in a 35 mm cell culture
dish. After 1 h post infection (pi), the medium was re-
moved and replaced with 2 mL of pre-warmed DMEM
containing 3% fetal calf serum. The dish was placed in
the 37 °C observation chamber containing 5% CO2
(Leica CTR-Controller 3700, Wetzlar, Germany). EGFP
fluorescence and phase contrast images were captured
every 15 min for a period of 3 days by a live cell station
(Leica AF6000, Wetzlar, Germany). Subsequently, images
were processed into a movie of six frames s-1 using
QuickTime Pro.
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Marc-145 cells (2 × 102/well) were cultured in 96-well
plates. Swine antiserum to HP-PRRSV/SD16 and nega-
tive serum were inactivated by heating at 56 °C for
30 min before testing. The inactivated serum was serially
two-fold diluted and 80 μL of each diluted serum was
mixed with equal volume of rHP-PRRSV/SD16/TRS6-
EGFP or wt HP-PRRSV/SD16 (100 TCID50/well) and
then incubated at 37 °C for 1 h. The mixture of virus
and serum was added to each of the wells plated with
the monolayered Marc-145 cells and incubated at 37 °C
for 1 h. The cells were washed twice with DMEM, and
then cultured in DMEM containing 3% FBS at 37 °C, 5%
CO2 for 48 h. The EGFP fluorescence and CPE were im-
aged using a fluorescence microscope (Leica, Germany).
Applicability of EGFP-tagged HP-PRRSV to screen antiviral
compound
The effect of antiviral compound CsA on HP-PRRSV
replication was investigated. Marc-145 cells were in-
fected with rHP-PRRSV/SD16/TRS6-EGFP (0.1 MOI)
for 1 h. The plates were washed with DMEM and the
various concentrations of CsA (0.25–64 μM) were
added. After 36 h pi, Marc-145 cells were fixed and ex-
amined under the fluorescent microscope. The effect of
CsA on cell viability was determined at 36 h after treat-
ment with CsA using a CellTiter 96 A Queous nonradio-
active cell proliferation assay (Promega) according to the
manufacturer’s instructions. To determine the effect of
CsA treatment on the production of infectious virus pro-
geny, Marc-145 cells were infected with rHP-PRRSV/
SD16/TRS6-EGFP or HP-PRRSV/SD16 at 0.1 MOI and
treated with CsA at various concentrations (2–8 μM) for
24 h. The virus was titered from the supernatants using
the Reed-Muench method. To verify the inhibition ofFigure 2 Characterisation of recombinant rHP-PRRSV/SD16/TRS6-EGF
A. Marc-145 cells infected with rHP-PRRSV/SD16/TRS6-EGFP and HP-PRRSV/
Living cells were analysed by phase contrast and fluorescence microscopy.
cells infected with wild-type HP-PRRSV/SD16 or recombinant rHP-PRRSV/SDEGFP-tagged HP-PRRSV replication by CsA, Marc-145
cells were infected with rHP-PRRSV/SD16/TRS6-EGFP
at 0.01MOI, and then treated with CsA at 2 to 16 μM
for 1 h. At 36 h pi, cells were lysed and viral proteins
were detected by Western blot analysis. Cellular proteins
from mock-infected Marc-145 cells were used as
controls.
Results
Rescue of rHP-PRRSV/SD16 and EGFP expression of rHP-
PRRSV/SD16/TRS6-EGFP
The recombinant rHP-PRRSV/SD16 and rHP-PRRSV/
SD16/TRS6-EGFP viruses were rescued successfully in
Marc-145 cells and rHP-PRRSV/SD16/EGFP was used
in the following experiments since it can be used for
evaluating or optimizing the reverse genetics system.
The recombinant rHP-PRRSV/SD16/TRS6-EGFP was
recovered in 60–80% of Marc-145 cells transfected using
the optimal ratios of plasmid and transfection reagent.
Marc-145 cells transfected with pBAC-SD16FL-TRS6-
EGFP showed a strong EGFP signal and infected cells
were easily observed by live cell imaging (Figure 2a and
Additional file 1). From the initial observations of the in-
fected cells, it appears that EGFP was present in cells in
early stages of infection when the CPE was not apparent.
This clearly shows that only Marc-145 cells infected with
rHP-PRRSV/SD16/TRS6-EGFP showed the expected
green fluorescence (Figure 2a). To confirm that EGFP
was expressed in rHP-PRRSV/SD16/TRS6-EGFP-infected
cells, EGFP and PRRSV N protein expression was ana-
lysed by Western blot using anti-GFP and 6D10 anti-
bodies, respectively. As shown in Figure 2b, normal viral
protein expression and EGFP expression were simultan-
eously detected in rHP-PRRSV/SD16/TRS6-EGFP in-
fected cells. However, EGFP expression was not detectedP containing an encoding EGFP as a separate transcription unit.
SD16 were observed for CPE and fluorescence detection, respectively.
B. Western blot analysis of virus N protein and EGFP levels in Marc-145
16/TRS6-EGFP.
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(Figure 2b).
Replication properties of recombinant viruses and
stability of EGFP
To determine whether the rescue procedure or exogen-
ous gene insertion affected the replicate ability of the re-
combinant virus, growth curves of HP-PRRSV/SD16 and
rHP-PRRSV/SD16/TRS6-EGFP in Marc-145 cells were
determined. The growth characteristics of rHP-PRRSV/
SD16/TRS6-EGFP were evaluated in a time-course ex-
periment and were compared with those of the parental
virus. rHP-PRRSV/SD16/TRS6-EGFP growth rate and
maximum titre were similar to those of the parental
virus (Figure 3a). To determine whether repeated pas-
sage of rHP-PRRSV/SD16/TRS6-EGFP in Marc-145 cells
affected replication and expression as well as the stability
of the EGFP insertion, rHP-PRRSV/SD16/TRS6-EGFP
was propagated and assessed by monitoring EGFP ex-
pression in Marc-145 cells for 10 passages. The samples
of culture medium plus cells collected every second pas-
sage were assayed for total (cell-associated and released
into culture media) virus titre and for EGFP expression
quantification detection. The results show that the virus
titre (Figure 3b) and EGFP expression (Figure 3c) from
different passages was kept almost constant. To deter-
mine whether the EGFP gene was stable and no ex-
pected mutations or deletions were incorporated into
the genome, intracellular RNA was isolated after infec-
tion with viruses from passages 5 and 10 (P5 and P10,
respectively) and subjected to RT-PCR and direct se-
quence analysis. The results demonstrate that the intact
EGFP gene was detected in both P5 and P10 samples,
indicating that at least during propagation in cell cultureFigure 3 Growth and stability of rHP-PRRSV/SD16/TRS6-EGFP in Marc
rHP-PRRSV/SD16/TRS6-EGFP and the amount of virus in the cultures was m
EGFP was passaged in Marc-145 cells every 3–4 days. The cells of each pas
EGFP expression throughout virus passages in Marc-145 cells was analysed
Data were expressed as the mean ± standard deviation (SD).rHP-PRRSV/SD16/TRS6-EGFP was stable and that its
growth kinetics were similar to those of the parental virus.Cell to cell spread of rHP-PRRSV/SD16/TRS6-EGFP
The spread of rHP-PRRSV/SD16/TRS6-EGFP in Marc-
145 cells was analysed by live-cell imaging to test
whether the EGFP-tagged viruses are useful in real-time
imaging. Marc-145 cells were infected with rHP-PRRSV/
SD16/TRS6-EGFP at a MOI of 0.1 and the cell mono-
layer was analysed by collecting EGFP fluorescence and
phase contrast photomicrographs. Photomicrographs of
10 different positions were captured every 15 min from
1 h pi for a period of 3 days (Additional file 1). Individ-
ual infected cells expressing EGFP were observed at
about 10 h pi and EGFP expression in neighbouring cells
was detected between 10 and 11 h later with a mean
value of 10.5 h, which correlates with the PRRSV repli-
cation cycle of approximately 10 h [24]. Moreover, EGFP
expression in surrounding cells was observed as late as
24 h pi in some infectious positions and EGFP fluores-
cence was distributed evenly on the monolayer in the
late infection stage. In addition, observation of infected
cells shows that EGFP was initially present in cells with-
out CPE. Therefore, detection of fluorescence could be
an early indicator of PRRSV infection in the cells. On
one hand, single infected cells were observed in early in-
fection, and then the infection spread to cells in close
proximity to the initially infected cell (Additional file 1).
On the other hand, virus spread could be promoted by
viral replication in actively dividing cells (Additional file 1).
Overall, these data suggest that PRRSV spread occurred
by direct cell to cell contact rather than by release of in-
fectious viral particles to the medium.-145 cells. A. Marc-145 cells were infected with HP-PRRSV/SD16 or
easured at various times from 12 to 96 h pi. B. rHP-PRRSV/SD16/TRS6-
sage were freeze-thawed three times and used for virus titration. C.
by quantitating relative fluorescence using a GFP Quantification Kit.
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Antiserum from a pig infected with HP-PRRSV/SD16 was
used to neutralise rHP-PRRSV/SD16/TRS6-EGFP and wt
HP-PRRSV/SD16 infections of Marc-145 cells at 48 h pi.
As shown in Figure 4, the antiserum diluted from 1:2 to
1:8 neutralised both rHP-PRRSV/SD16/TRS6-EGFP and
wt HP-PRRSV/SD16 virus infection of Marc-145 cells as
shown by EGFP fluorescence and CPE, whereas the nega-
tive serum did not neutralise the virus infection. These
data indicate that rHP-PRRSV/SD16/TRS6-EGFP virus is
a useful tool for screening neutralising antibodies.
CsA inhibited the replication of EGFP-tagged HP-PRRSV
The effect of CsA on HP-PRRSV replication was investi-
gated using rHP-PRRSV/SD16/TRS6-EGFP and wt HP-
PRRSV. As shown in Figure 5a, CsA inhibited HP-PRRSV/
SD16/TRS6-EGFP infection of Marc-145 cells in a doseFigure 4 Neutralisation of rHP-PRRSV/SD16/TRS6-EGFP infection. The
incubated with serial dilutions of either a HP-PRRSV/SD16 antiserum or
fluorescence and CPE were analysed at 48 h pi using a Leica confocal m
tested in triplicate.dependent manner as indicated by the EGFP signal. At the
concentration of 16 μM, the EGFP signal was hardly de-
tected (Figure 5a), and the replication of rHP-PRRSV/
SD16/TRS6-EGFP was completely blocked by CsA at 64 μM.
CsA had only a slight effect on cell viability (Figure 5b).
The production of rHP-PRRSV/SD16/TRS6-EGFP and wt
HP-PRRSV infectious progeny were greatly reduced by
CsA at the concentrations of 2 μM to 8 μM in a dose
dependent manner (Figure 5c). The effect of CsA on the
production of the viral proteins was evaluated by the
Western blot. As shown in Figure 5d, the levels of viral
structural proteins M and N and EGFP proteins were
markedly reduced by CsA in a dose dependent manner.
Discussion
Here, we report the rescue of a recombinant HP-PRRSV
carrying an EGFP reporter gene as a separate transcriptionrHP-PRRSV/SD16/TRS6-EGFP and HP-PRRSV/SD16 viruses were
a negative serum, and then used to infect Marc-145 cells. The EGFP
icroscope at a magnification of × 250. Each serum dilution was
Figure 5 CsA inhibits EGFP-tagged HP-PRRSV replication. A. CsA at various concentrations inhibited rHP-PRRSV/SD16/TRS6-EGFP infection of
Marc-145 cells as shown by the relative EGFP fluorescence expression normalised to the EGFP signal in solvent-treated control cells (100%). B. The
effect of CsA at various concentrations on cell viability compared to the viability of untreated control cells (100%) was determined using a
CellTiter 96 A Queous nonradioactive cell proliferation assay at 36 h after treatment with CsA. C. CsA at various concentrations inhibited rHP-PRRSV/
SD16/TRS6-EGFP and wt HP-PRRSV/SD16 infection of Marc-145 cells by determining the virus titers in the supernatants at 24 h pi. D. CsA at various
concentrations inhibited the levels of rHP-PRRSV/SD16/TRS6-EGFP structural proteins N and M and EGFP protein by Western blot analysis.
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tion of HP-PRRSV as an expression vector, we first se-
lected the sites of insertion. American types of PRRSV
have only two non-overlapping regions located between
ORF1b and ORF2a, as well as between ORF4 and ORF5
of the genome. Since these intergenic regions are reduced
in size (about 11 to 220 nts), the insertion of an extra cas-
sette could alter the expression of the ORF downstream
from the insertion site due to the proximity to the TRS of
the next gene [48]. Except for the intergenic regions, the
extra cassette can also be inserted just before the ORF1,
or after the ORF7 regions since there were no overlapping
genes. Insertions before ORF1 may block the early transla-
tion of pp1a and pp1ab, which are responsible for the sub-
sequent replication and formation of subgenomic mRNA.
As a result, the site between N gene and 3′-UTR was
chosen for the insertion. Secondly, the TRS6 was chosen
because it had the shortest distance (24-bp) between the
body TRS and downstream ORF. Taken together, thisposition was selected for the insertion of a copy of the
TRS6 in order to drive transcription of EGFP as a separate
transcription unit.
In previous studies, recombinant PRRSV including a
foreign HA tag fused to ORF7 started to lose the intro-
duced epitope at passage 2 and continued to lose with
the increasing number of passages [43]. In a recombin-
ant PRRSV expressing GFP gene fused to the nsp2 gene,
the heterologous insertion was lost after 7 serial passages
due to a N-terminal deletion of GFP from aa 1 to 159
[44]. Similarly, the foreign EGFP gene was lost after 5
serial passages due to a single aa mutation [45]. How-
ever, a recombinant PRRSV expressing GFP gene with
an extra TRS-ORF cassette inserted between ORF1ab
and ORF2 was stable even after 37 serial passages using
TRS2 to drive transcription of the GFP gene and insert-
ing an extra synthetic TRS6 to drive transcription of the
ORF 2a and 2b genes [22]. Taken together, these data
show that PRRSV can tolerate the addition of a foreign
Wang et al. Veterinary Research 2013, 44:104 Page 9 of 11
http://www.veterinaryresearch.org/content/44/1/104gene at specific positions, although the insertion of extra
non-viral genetic material may lead to the reduction of
the level of the viral replication or result in variants that
no longer encode a functional foreign gene. In an at-
tempt to circumvent these disadvantages and to reduce
to a minimum the modification of the PRRSV genome,
we cloned the heterologous gene between N gene and 3′
UTR using a BAC approach to recover recombinant HP-
PPRSV [46,47,49-52]. The EGFP was introduced into the
HP-PRRSV/SD16 genome with limited modification of
the genome to create a marked recombinant PPRSV,
rHP-PRRSV/SD16/TRS6-EGFP, which stably expressed
EGFP as a separate transcription unit. Importantly, rHP-
PRRSV/SD16/TRS6-EGFP shows similar patterns in
growth rate and maximum titre in comparison with the
parental virus.
Our results show that Marc-145 cells transfected with
pBAC-SD16FL-TRS6-EGFP produced both green fluores-
cent cells and viral progeny. Insertion of EGFP as a separ-
ate transcription unit did not affect replication of the
recombinant virus in the infected cells. Furthermore, the
fact that EGFP fluorescence in EGFP recombinant viruses
was expressed stable and at higher levels in different pas-
sages, suggests that the cDNA infectious clone represents
a useful tool for construction of potential recombinant
vaccine candidates, in which the EGFP ORF can be re-
placed by sequences encoding immunogenic antigens of
other viruses. Overall, the virus recovered from the infec-
tious cDNA clone exhibited the same genotypic and
phenotypic properties as the parental virus.
The infection of cells with rHP-PRRSV/SD16/EGFP
can be used as an excellent model to study the release of
infectious PRRSV and virion formation in infected cells.
Early observation of infected cells showed that EGFP
was expressed in cells with no apparent CPE. This could
be due to high expression levels associated with genes
located close to the genome end. In addition, EGFP may
passively spread into adjacent cells through cell-to-cell-
contact from the earlier infected cells. Therefore, the de-
tection of fluorescence could be more sensitive than
PRRSV antigen detection. Finally, PRRSV replication was
observed in actively dividing Marc-145 cells, indicating
that PRRSV could infect quiescent and dividing cells.
These results clearly show that EGFP fluorescence can
be an early indicator of the infection in cells and a useful
tool to show the processes of the rapid spread of PRRSV
from cell to cell. In addition, the rHP-PRRSV/SD16/
TRS6-EGFP was found to be an excellent tool for screen-
ing neutralising antibodies.
Previously, the drug CsA was demonstrated to inhibit
the replication of a variety of RNA viruses using different
pathways including herpes simplex virus, human im-
munodeficiency virus type 1, hepatitis C virus and influ-
enza virus [53-56]. In the present study, we demonstratethat CsA inhibited the HP-PRRSV replication in Marc-
145 cells in a dose dependent manner (Figure 5). These
results were in accordance with a previous study showing
that CsA inhibits arterivirus replication by interfering with
viral RNA synthesis [57].
In conclusion, we report the rescue of a recombinant
PRRSV carrying an EGFP reporter gene as a separate
transcription unit. The PRRSV reverse genetics system
used is highly flexible and may facilitate the engineering
of recombinant multivalent vaccines by replacing the
EGFP ORF sequences encoding immunogenic antigens
from another virus. The generation of an EGFP- express-
ing HP-PRRSV could be a useful tool not only to monitor
virus spread and screen for antiviral compounds and neu-
tralising antibodies, but also for fundamental research on
the biology of the virus.Additional file
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